Literature DB >> 6722822

Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells.

T Lee, D Roberts.   

Abstract

The flux of teniposide (VM-26) across the cell membrane was compared for L1210 cells, nine VM-26-resistant L1210 sublines, and three partially revertant lines. The nine resistant sublines were maintained in medium with VM-26. A "zero-time," temperature-independent binding of VM-26 to cells, attributable to adsorption on the cell membrane or to solvation in the membrane, varied independently of the sensitivity of cell lines to the drug as measured by the extracellular concentration of drug required to inhibit growth of a subline by 50% at the end of 24 hr (IC50). The IC50 values varied from 22 nM VM-26 for parental cells to 45 microM VM-26 for the most resistant subline. After subtraction of the zero-time values, the initial rates of influx for VM-26 (extracellular concentration, 20.5 microM) and the apparent equilibrium constants for the flux of drug across the cell membrane correlated inversely with the logarithm of the IC50 values. Cellular steady-state levels of VM-26, initial rates of efflux of the drug, and cellular levels of nondiffusible drug varied independently of the IC50 values but in relation to each other. The efflux of VM-26 from the sublines was faster than from the parental cells at both 4 degrees and at 37 degrees. We conclude that resistance of L1210 cells to VM-26 is associated with changes in the flux of the drug across the cell membrane.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6722822

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Association of sorcin with drug resistance in L1210 cells.

Authors:  D Roberts; M B Meyers; J L Biedler; L G Wiggins
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells.

Authors:  D Roberts; T Lee; E Parganas; L Wiggins; J Yalowich; R Ashmun
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Reduced formation of lesions in the DNA of a multidrug-resistant L1210 subline selected for teniposide resistance.

Authors:  D W Roberts; P D Foglesong; E Parganas; L Wiggins
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 5.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.